KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) EBITDA (2019 - 2025)

Royalty Pharma's EBITDA history spans 7 years, with the latest figure at $388.4 million for Q4 2025.

  • For Q4 2025, EBITDA rose 7.43% year-over-year to $388.4 million; the TTM value through Dec 2025 reached $1.6 billion, up 20.66%, while the annual FY2025 figure was $1.6 billion, 20.66% up from the prior year.
  • EBITDA for Q4 2025 was $388.4 million at Royalty Pharma, down from $427.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $735.1 million in Q3 2024 and bottomed at -$482.7 million in Q4 2022.
  • The 5-year median for EBITDA is $259.2 million (2023), against an average of $269.7 million.
  • The largest annual shift saw EBITDA plummeted 414.6% in 2022 before it skyrocketed 824.08% in 2025.
  • A 5-year view of EBITDA shows it stood at $153.4 million in 2021, then tumbled by 414.6% to -$482.7 million in 2022, then skyrocketed by 226.98% to $612.9 million in 2023, then tumbled by 41.02% to $361.5 million in 2024, then increased by 7.43% to $388.4 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's EBITDA are $388.4 million (Q4 2025), $427.2 million (Q3 2025), and $209.8 million (Q2 2025).